Pharming Group (PHGUF) Receives a Rating Update from a Top Analyst
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Pharming Group (PHGUF) today and set a price target of EUR3.10. The company’s shares closed last Tuesday at $1.30.
According to TipRanks.com, Pantginis is a top 25 analyst with an average return of 47.6% and a 66.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $3.74.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.85 and a one-year low of $0.83. Currently, Pharming Group has an average volume of 10.01K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.